The preliminary revenue beat and narrowed guidance suggest operational momentum. Full Q3 results on October 27 will provide EPS, cash flow, and updated pipeline timelines — key catalysts for the stock.
Price Chart
Executive Summary
Pharming Group N.V. released preliminary Q3 2026 revenue above market expectations, with total revenues of ~US$117.6M (+21% YoY) driven by RUCONEST and Joenja. The company tightened full-year 2026 revenue guidance to US$380M–US$390M and lowered operating expense guidance. Full Q3 results and a business update are scheduled for October 27, 2026.
Key Facts
- Q3 2026 total revenues ~US$117.6M, up 21% YoY from US$97.3M in Q3 2025
- RUCONEST revenue ~US$93.8M (+14% YoY, +30% QoQ)
- Joenja revenue ~US$23.8M (+58% YoY)
- Total operating expenses ~US$74.6M, in line with Q3 2025
- 2026 revenue guidance tightened to US$380M–US$390M (from US$375M–US$395M)
- 2026 operating expense guidance lowered to US$310M–US$315M (from US$315M–US$320M)
- Full Q3 results and business update moved forward to October 27, 2026
- Topline Phase II results for leniolisib in CVID expected November 2026
- FALCON trial enrollment for napazimone expected to complete H1 2027
Financial Impact
Q3 2026 revenue beat market expectations by an undisclosed amount; 2026 revenue guidance midpoint raised to US$385M from US$385M (unchanged midpoint but range narrowed); operating expense guidance lowered by ~US$5M at midpoint.
Risk Factors
- RUCONEST revenue includes a one-time seasonal channel inventory build at a single specialty pharmacy customer
- Joenja international ordering patterns may normalize, reducing sequential growth
- FALCON trial enrollment delayed to H1 2027, pushing topline results to ~H1 2028
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000047 |
| Document: 0001828316-26-000047-index-headers.html | 0001828316-26-000047 |
| Document: 0001828316-26-000047-index.html | 0001828316-26-000047 |
| Document: 0001828316-26-000047.txt | 0001828316-26-000047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $11.55 | awaiting T+1 | — | $11.87 (+2.77%) |
Oct 27, 2026 today | Press Release | $11.55 | awaiting T+1 | — | $11.87 (+2.77%) |
Oct 22, 2026 5d ago | 6-K | $10.67 $11.20 | ▲ +4.97% | ▲ +5.49% | $11.87 (+11.25%) |
Oct 14, 2026 13d ago | 6-K | $9.64 $9.63 | ▼ −0.10% | ▼ −0.39% | $11.87 (+23.13%) |
Sep 29, 2026 28d ago | 6-K | $10.01 $9.99 | ▲ +0.20% | ▼ −0.01% | $11.87 (−18.58%) |
Sep 29, 2026 28d ago | Press Release | $10.01 $9.99 | ▲ +0.20% | ▼ −0.01% | $11.87 (−18.58%) |
Sep 25, 2026 4w ago | 6-K | $10.46 $10.52 | ▲ +0.57% | ▲ +1.32% | $11.87 (+13.48%) |
Sep 25, 2026 4w ago | Press Release | $10.46 $10.52 | ▲ +0.57% | ▲ +1.32% | $11.87 (+13.48%) |
Sep 22, 2026 5w ago | 6-K | $11.26 $10.77 | ▼ −4.35% | ▼ −3.63% | $11.87 (+5.42%) |
Sep 11, 2026 6w ago | 6-K | $11.21 $10.82 | ▼ −3.48% | ▼ −3.03% | $11.87 (+5.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers